1. Kalhor E, Noori A, Saboori Rad S, Sadrnia MA. [Using eligibility traces algorithm to specify the optimal dosage for the purpose of cancer cell population control in melanoma patients with a consideration of the side effects (Persian)]. J Soft Comput Inf Technol. 2021; 10(1):72-92. [Link]
2. Domingues B, Lopes JM, Soares P, Pópulo H. Melanoma treatment in review. Immunotargets Ther. 2018; 7:35-49. [DOI:10.2147/ITT.S134842] [PMID] [PMCID] [
DOI:10.2147/ITT.S134842]
3. Fidanzi C, D'Erme AM, Janowska A, Dini V, Romanelli M, Manzo Margiotta F, et al. Epidemiology of melanoma: The importance of correctly reporting to the cancer registries. Eur J Cancer Prev. 2022; 31(4):385-7. [DOI:10.1097/CEJ.0000000000000747] [PMID] [
DOI:10.1097/CEJ.0000000000000747]
4. Inthiyaz S, Altahan BR, Ahammad SH, Rajesh V, Kalangi RR, Smirani LK, et al. Skin disease detection using deep learning. Adv Eng Softw. 2023; 175:103361. [DOI:10.1016/j.advengsoft.2022.103361] [
DOI:10.1016/j.advengsoft.2022.103361]
5. Mahdavirad M, Najafzadeh N, Ali Niapour A, Jafari A. [Cytotoxicity of Zno and Ag/Zno nano-composites on malignant melanoma cell line (A375) (Persian)]. Arak Med Univ J. 2014; 17(6):74-83. [Link]
6. Jenkins RW, Fisher DE. Treatment of advanced melanoma in 2020 and beyond. J Invest Dermatol. 2021; 141(1):23-31. [DOI:10.1016/j.jid.2020.03.943] [PMID] [PMCID] [
DOI:10.1016/j.jid.2020.03.943]
7. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol. 1993; 11(3):570-9. [DOI:10.1200/JCO.1993.11.3.570] [PMID] [
DOI:10.1200/JCO.1993.11.3.570]
8. Barakat H, Aljutaily T, Almujaydil MS, Algheshairy RM, Alhomaid RM, Almutairi AS, et al. Amygdalin: A review on its characteristics, antioxidant potential, gastrointestinal microbiota intervention, anticancer therapeutic and mechanisms, toxicity, and encapsulation. Biomolecules. 2022; 12(10):1514. [DOI:10.3390/biom12101514] [PMID] [PMCID] [
DOI:10.3390/biom12101514]
9. Shi J, Chen Q, Xu M, Xia Q, Zheng T, Teng J, et al. Recent updates and future perspectives about amygdalin as a potential anticancer agent: A review. Cancer Med. 2019; 8(6):3004-11. [DOI:10.1002/cam4.2197] [PMID] [PMCID] [
DOI:10.1002/cam4.2197]
10. Saleem M, Asif J, Asif M, Saleem U. Amygdalin from apricot kernels induces apoptosis and causes cell cycle arrest in cancer cells: An updated review. Anticancer Agents Med Chem. 2018; 18(12):1650-5. [DOI:10.2174/1871520618666180105161136] [PMID] [
DOI:10.2174/1871520618666180105161136]
11. Moertel CG, Fleming TR, Rubin J, Kvols LK, Sarna G, Koch R, et al. A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med. 1982; 306(4):201-6. [DOI:10.1056/NEJM198201283060403] [PMID] [
DOI:10.1056/NEJM198201283060403]
12. Tsaur I, Thomas A, Monecke M, Zugelder M, Rutz J, Grein T, et al. Amygdalin exerts antitumor activity in taxane-resistant prostate cancer cells. Cancers. 2022; 14(13):3111. [DOI:10.3390/cancers14133111] [PMID] [PMCID] [
DOI:10.3390/cancers14133111]
13. Ramachandran V, Hosalli KR, Vijayakumar I, Mani L, Tiwari R, Tiwari G. A review on antitumor action of amygdalin on various types of cancers. Res J Pharm Technol. 2022; 15(11):5373-80. [DOI:10.52711/0974-360X.2022.00906] [
DOI:10.52711/0974-360X.2022.00906]
14. Cecarini V, Selmi S, Cuccioloni M, Gong C, Bonfili L, Zheng Y, et al. Targeting proteolysis with cyanogenic glycoside amygdalin induces apoptosis in breast cancer cells. Molecules. 2022; 27(21):7591. [DOI:10.3390/molecules27217591] [PMID] [PMCID] [
DOI:10.3390/molecules27217591]
15. Makarević J, Tsaur I, Juengel E, Borgmann H, Nelson K, Thomas C, et al. Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro. Life Sci. 2016; 147:137-42. [DOI:10.1016/j.lfs.2016.01.039] [PMID] [
DOI:10.1016/j.lfs.2016.01.039]
16. Park HJ, Yoon SH, Han LS, Zheng LT, Jung KH, Uhm YK, et al. Amygdalin inhibits genes related to cell cycle in SNU-C4 human colon cancer cells. World J Gastroenterol. 2005; 11(33):5156-61. [DOI:10.3748/wjg.v11.i33.5156] [PMID] [PMCID]
17. Aamazadeh F, Ostadrahimi A, Rahbar Saadat Y, Barar J. Bitter apricot ethanolic extract induces apoptosis through increasing expression of Bax/Bcl-2 ratio and caspase-3 in PANC-1 pancreatic cancer cells. Mol Biol Rep. 2020; 47(3):1895-904. [DOI:10.1007/s11033-020-05286-w] [PMID] [
DOI:10.1007/s11033-020-05286-w]
18. Prajapati M, Deshmukh R, Harwansh RK. Recent trends in nanoparticulate delivery system for amygdalin as potential therapeutic herbal bioactive agent for cancer treatment. In: Prajapati M, Deshmukh R, Harwansh RK , editors. Current drug delivery. Sharjah: Bentham Science Publishers; 2024. [Link] [
DOI:10.2174/0115672018280381231119150732]
19. He XY, Wu LJ, Wang WX, Xie PJ, Chen YH, Wang F. Amygdalin - A pharmacological and toxicological review. J Ethnopharmacol. 2020; 254:112717. [DOI:10.1016/j.jep.2020.112717] [PMID] [
DOI:10.1016/j.jep.2020.112717]
20. Chen Y, Ma J, Wang F, Hu J, Cui A, Wei C, et al. Amygdalin induces apoptosis in human cervical cancer cell line HeLa cells. Immunopharmacol Immunotoxicol. 2013; 35(1):43-51. [DOI:10.3109/08923973.2012.738688] [PMID] [
DOI:10.3109/08923973.2012.738688]
21. Makarević J, Rutz J, Juengel E, Kaulfuss S, Reiter M, Tsaur I, et al. Amygdalin blocks bladder cancer cell growth in vitro by diminishing cyclin A and cdk2. Plos One. 2014; 9(8):e105590. [DOI:10.1371/journal.pone.0105590] [PMID] [PMCID] [
DOI:10.1371/journal.pone.0105590]
22. Chang HK, Shin MS, Yang HY, Lee JW, Kim YS, Lee MH, et al. Amygdalin induces apoptosis through regulation of Bax and Bcl-2 expressions in human DU145 and LNCaP prostate cancer cells. Biol Pharm Bull. 2006; 29(8):1597-602. [DOI:10.1248/bpb.29.1597] [PMID] [
DOI:10.1248/bpb.29.1597]